



SARS spike glycoprotein (16F1071): sc-52954

BACKGROUND

Severe acute respiratory syndrome (SARS), a recently emergent respiratory disease characterized by atypical pneumonia with short 2-7 day incubation periods, is caused by a coronavirus. Sharing little homology with previously known coronaviruses, the SARS virus seems to be the first coronavirus that consistently causes severe disease in humans. Coronaviruses maintain enveloped structures, utilizing positive-sense single-stranded RNA to replicate in the cytoplasm of host cells. Coronavirus RNA synthesis retains a very high rate of RNA-RNA recombination, allowing extensive evolution of unique species such as SARS. Most viral particles show the appearance of spike-like glycoprotein surface projections, giving rise to the virus' name, which is Latin for crown. These transmembrane spike glycoproteins protrude 20 nanometers from the surface.

REFERENCES

1. He, L., Ding, Y., Zhang, Q., Che, X., He, Y., Shen, H., Wang, H., Li, Z., Zhao, L., Geng, J., Deng, Y., Yang, L., Li, J., Cai, J., Qiu, L., Wen, K., Xu, X. and Jiang, S. 2006. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2⁺ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. *J. Pathol.* 210: 288-297.
2. Cheng, C., Wong, W.M. and Tsang, K.W. 2006. Perception of benefits and costs during SARS outbreak: An 18-month prospective study. *J. Consult. Clin. Psychol.* 74: 870-879.
3. Ren, W., Li, W., Yu, M., Hao, P., Zhang, Y., Zhou, P., Zhang, S., Zhao, G., Zhong, Y., Wang, S., Wang, L.F. and Shi, Z. 2006. Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. *J. Gen. Virol.* 87: 3355-3359.
4. Shao, H., Lan, D., Duan, Z., Liu, Z., Min, J., Zhang, L., Huang, J., Su, J., Chen, S. and Xu, A. 2006. Upregulation of mitochondrial gene expression in PBMC from convalescent SARS patients. *J. Clin. Immunol.* 26: 546-554.
5. Liu, M., Gu, C., Wu, J. and Zhu, Y. 2006. Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2. *Virus Genes* 33: 309-317.
6. Kuba, K., Imai, Y., Rao, S., Jiang, C. and Penninger, J.M. 2006. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. *J. Mol. Med.* 84: 814-820.
7. Al-Hajjar, S. 2006. SARS: Challenge of the new century. *Ann. Saudi Med.* 23: 116-117.
8. Smith, R.D. 2006. Responding to global infectious disease outbreaks: lessons from role of risk perception, communication and management. *Soc. Sci. Med.* 63: 3113-3123.
9. Stockman, L.J., Bellamy, R. and Garner, P. 2006. SARS: systematic review of treatment effects. *PLoS Med.* 3: 343.

SOURCE

SARS spike glycoprotein (16F1071) is a mouse monoclonal antibody raised against a SARS spike glycoprotein corresponding to amino acids 19-35.

PRODUCT

Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

SARS spike glycoprotein (16F1071) is recommended for detection of SARS spike glycoprotein by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Molecular Weight of SARS spike glycoprotein: 440-669 kDa.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.